Scott Smith joined the Viatris board of directors in December 2022 and has been appointed Chief Executive Officer of Viatris, effective April 1, 2023. Before being appointed CEO, Smith was President of BioAtla, Inc., a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics. He is a member of the BioAtla board of directors and is Chairman of the board of Triumvira Immunologics.
Smith previously served on the boards of directors of Refuge Biotechnologies, Inc., of Titan Pharmaceuticals, Inc., chairing the Compensation and Nominating and Governance Committees; and as Chairman of F-star Therapeutics, Inc., serving on that company’s Audit and Nominating and Corporate Governance Committees.
Previously, Smith was President and Chief Operating Officer at Celgene Corporation, rising up the ranks from SVP and Global Head of Immunology, and then President of Inflammation and Immunology.
He holds a BSc in Chemistry and Biology as well as an HBSc in Pharmacology and Toxicology from the University of Western Ontario and received his master’s degree in International Management from the American Graduate School of International Management (Thunderbird).
